Royalty Pharma plc - Class A ordinary shares, par value $0.0001 per share (RPRX)

CUSIP: G7709Q104

Q3 2026 13F Holders as of 30 Sep 2026

Holder snapshot 6 signals
Share change
+2,381,520
SEC-reported price per share
$58.36
Number of holders
199
Value change
+$139,505,752
Number of buys
108
Number of sells
66
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
543,437,496

Security key

G7709Q104

Report period

Q3 2026

Institutions

199

Top holders

10

Ownership snapshot

Top reported holders of RPRX - Royalty Pharma plc - Class A ordinary shares, par value $0.0001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Pablo G. Legorreta
Disclosed value leader
Pablo G. Legorreta
Comparable rows
8/15
Latest evidence
13 Aug 2026
13D/G 3/4/5 13F Lead comparable stake: 19% 7 rows are not safely comparable across share classes. 13D/G row: Pablo G. Legorreta Showing 1-6 of 15 holder rows.

Quick read

Pablo G. Legorreta leads the comparable SEC ownership view at 19%.

8 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Pablo G. Legorreta's linked filing trail.
Comparable ownership Top 5
Pablo G. Legorreta 19%
MORGAN STANLEY 9.2%
Capital International Investors 8.8%
FMR LLC 6.5%
BlackRock, Inc. 5.7%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Pablo G. Legorreta
13D/G 3/4/5
Legorreta G. Pablo · CEO, Chairman of the Board, Director
19%
Reported 13D/G · 13 Aug 2026
$5,677,614,323
101,785,843 shares
-$74,017,438 13 Aug 2026
MORGAN STANLEY
13F 13D/G
Company
9.2%
Reported 13D/G · 30 Jun 2025
$2,407,174,722
42,931,597 shares
— 30 Jun 2026
Capital International Investors
13F 13D/G
Company
8.8%
Reported 13D/G · 31 Mar 2026
$1,977,800,284
35,273,770 shares
— 30 Jun 2026
FMR LLC
13F 13D/G
Company
6.5%
Reported 13D/G · 30 Sep 2025
$1,374,489,542
24,513,814 shares
— 30 Jun 2026
BlackRock, Inc.
13F 13D/G
Company
5.7%
Reported 13D/G · 31 Dec 2024
$1,560,595,060
27,832,977 shares
— 30 Jun 2026
Severgnini Achille G.
13D/G
4.8%
Reported 13D/G · 12 Jun 2026
$1,164,070,183
21,366,927 shares
-$155,603,324 12 Jun 2026
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q3 2026

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
199
Shares
25,976,610
Rows available
199
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q3 2026 vs Q2 2026 Across Filers

Q2 2026 holders
646
Q3 2026 holders
199
Holder diff
-447
Investor Q2 2026 Shares Q3 2026 Shares Share Diff Share Chg % Q2 2026 value Q3 2026 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .